PAVmed (PAVM) Amortization of Deferred Charges (2017 - 2018)

PAVmed (PAVM) recorded quarterly Amortization of Deferred Charges of $505848.0 in Q3 2018, up 65.45% quarter-over-quarter from $305734.0 in Q2 2018.

PAVmed (PAVM) Amortization of Deferred Charges (2017 - 2018) Analysis & Trends

PAVmed's Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $505848.0 for Q3 2018.

In Q3 2018, Amortization of Deferred Charges changed N/A year-over-year to $505848.0; the TTM figure through Sep 2018 stood at $1.3 million (changed N/A YoY), while the FY2017 annual figure was $347601.0, changed N/A from the prior year.
Amortization of Deferred Charges was $505848.0 for Q3 2018 at PAVmed, up from $305734.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $505848.0 in Q3 2018 to a low of $172959.0 in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	PAVmed	2.70 Mn	-10.47 Mn	-703,000.00

Download Data